Abstract: According to some embodiments, a device for assisting manipulation of an elongated member comprises a head member, at least one strap to secure to first and second ends of the head member, the at least one strap being sized and configured to extend around the elongated member, wherein the at least one strap is configured to tighten around the elongated member, wherein tightening of the at least one strap around the elongated member brings the head member toward an exterior surface of the elongated member, and a connector coupled to the head member, wherein the connector is configured to secure to an actuator or movable device in order to exert desired forces or moments to the device and the elongated member to which the device is secured, wherein use of the device eliminates the need for contact between a user and the elongated member.

Abstract: According to some embodiments, a device for reducing magnetic force along a section of piping comprises a first end member comprising an opening, a second end member comprising an opening, at least one connecting member extending between the first end member and the second end member, the at least one connecting member secured to both the first and second end members, wherein the at least one connecting member defines a passageway that generally aligns with the openings of the first and second end members, and wherein the passageway and the central openings of the first and second members are sized and otherwise configured to accommodate a pipe section. The device further includes a coil configured to conduct electrical current.

Abstract: The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.

Abstract: The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.